Valeant, Croma agreement to expand B + L surgical line

September 23, 2014

The recent agreement between Valeant and Croma-which would provide for the distribution of Croma’s ophthalmology products in Western Europe-is expected to expand Bausch + Lomb’s (B + L) ophthalmic portfolio in the United States.

 

Bridgewater, NJ-The recent agreement between Valeant and Croma-which would provide for the distribution of Croma’s ophthalmology products in Western Europe-is expected to expand Bausch + Lomb’s (B + L) ophthalmic portfolio in the United States.

Through the transaction, which was announced earlier this month, Valeant acquired hundreds of distinct medical products, including viscoelastics, IOLs, surgical instruments, dry eye, and anti-inflammatory pharmaceuticals. Since Croma’s products are not available in the United States, regulatory approvals will be necessary.

More in this issue: Nicox acquires rights to anti-viral drop; buys French ophthalmic firm

“We are committed to providing U.S. ophthalmic surgeons with the broadest product line in the industry, allowing them to make the right choices for their patients from an array of cataract, refractive, and retinal devices,” said Ari Kellen, MBBCh, MBA, head of U.S. eye health, B + L. “Our agreement with Croma gives us access to a rich basket of products on the European market today as well as others currently in development. This access is part of our ongoing strategy to grow our ophthalmic business and meet the needs of our U.S. customers.”

 

 

 

For more articles in this issue of Ophthalmology Times eReport, click here.

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.